106 related articles for article (PubMed ID: 23452312)
21. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
22. Pramlintide: FDA wants more.
Diabetes Obes Metab; 2001 Oct; 3(5):386. PubMed ID: 11710342
[No Abstract] [Full Text] [Related]
23. Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs.
Peyrot M; Rubin RR; Polonsky WH; Best JH
Curr Med Res Opin; 2010 May; 26(5):1047-54. PubMed ID: 20199136
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic management of the older patient with type 2 diabetes mellitus.
Neumiller JJ; Setter SM
Am J Geriatr Pharmacother; 2009 Dec; 7(6):324-42. PubMed ID: 20129254
[TBL] [Abstract][Full Text] [Related]
25. Quick-release bromocriptine for treatment of type 2 diabetes.
Mikhail N
Curr Drug Deliv; 2011 Sep; 8(5):511-6. PubMed ID: 21696353
[TBL] [Abstract][Full Text] [Related]
26. Pramlintide. AC 137, ACO 137, Normylin, Symlin, Tripro-amylin.
Drugs R D; 1999 Aug; 2(2):118-22. PubMed ID: 10820656
[No Abstract] [Full Text] [Related]
27. Bromocriptine: its place in type 2 diabetes Tx.
Sando KR; Taylor J
J Fam Pract; 2011 Nov; 60(11):E1-5. PubMed ID: 22049355
[TBL] [Abstract][Full Text] [Related]
28. Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.
Eržen S; Tonin G; Jurišić Eržen D; Klen J
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338796
[TBL] [Abstract][Full Text] [Related]
29. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
Aronne LJ; Halseth AE; Burns CM; Miller S; Shen LZ
Obesity (Silver Spring); 2010 Sep; 18(9):1739-46. PubMed ID: 20094043
[TBL] [Abstract][Full Text] [Related]
30. Amylin Pharmacology in Alzheimer's Disease Pathogenesis and Treatment.
Corrigan RR; Piontkivska H; Casadesus G
Curr Neuropharmacol; 2022; 20(10):1894-1907. PubMed ID: 34852745
[TBL] [Abstract][Full Text] [Related]
31. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
Lamos EM; Levitt DL; Munir KM
Prim Care Diabetes; 2016 Feb; 10(1):60-5. PubMed ID: 26670921
[TBL] [Abstract][Full Text] [Related]
32. Bromocriptine mesylate (Cycloset) for type 2 diabetes mellitus.
Weiland CM; Hilaire ML
Am Fam Physician; 2013 May; 87(10):718-20. PubMed ID: 23939451
[No Abstract] [Full Text] [Related]
33. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
Leinung MC; Grasso P
Regul Pept; 2012 Nov; 179(1-3):33-8. PubMed ID: 22960403
[TBL] [Abstract][Full Text] [Related]
34. Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study.
Pencek R; Roddy T; Peters Y; De Young MB; Herrmann K; Meller L; Nguyen H; Chen S; Lutz K
Diabetes Obes Metab; 2010 Jun; 12(6):548-51. PubMed ID: 20518811
[TBL] [Abstract][Full Text] [Related]
35. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
Amiel SA; Heller SR; Macdonald IA; Schwartz SL; Klaff LJ; Ruggles JA; Weyer C; Kolterman OG; Maggs DG
Diabetes Obes Metab; 2005 Sep; 7(5):504-16. PubMed ID: 16050943
[TBL] [Abstract][Full Text] [Related]
36. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
Schwartz SS; Zangeneh F
Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
[TBL] [Abstract][Full Text] [Related]
37. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.
Thompson RG; Gottlieb A; Organ K; Koda J; Kisicki J; Kolterman OG
Diabet Med; 1997 Jul; 14(7):547-55. PubMed ID: 9223392
[TBL] [Abstract][Full Text] [Related]
38. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
[TBL] [Abstract][Full Text] [Related]
39. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI
Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452
[TBL] [Abstract][Full Text] [Related]
40. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
